Selected angle: source

One-sentence thesis

The cited A/B receipts support a specific working claim: Inversely associated with lower risk of cancer mortality (RR: 0.86, 95% CI 0.81 to 0.91); The highest adherence score to an MD was significantly associated with a lower risk of all-cause cancer mortality (RR: 0.87, 95% CI 0.81-0.93). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

the surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in cohort studies, 14 studies; 1,784,404 subjects from 56 observational studies; meta-analysis of cohort studies on postmenopausal breast cancer. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.

Evidence Landscape

Bounded research question: Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

Evidence receipts

• fact_id=37011 (A_core) — Inversely associated with lower risk of cancer mortality (RR: 0.86, 95% CI 0.81 to 0.91) doi=10.3390/nu9101063
• fact_id=73642 (A_core) — The highest adherence score to an MD was significantly associated with a lower risk of all-cause cancer mortality (RR: 0.87, 95% CI 0.81-0.93) doi=10.1002/cam4.539
• fact_id=73915 (A_core) — summary HR for high versus low MD adherence was 0.94 for total postmenopausal breast cancer doi=10.1002/ijc.30654
• fact_id=73679 (A_core) — stroke incidence (RR: 0.80; 95% CI: 0.71, 0.90) doi=10.1080/10408398.2019.1565281
• fact_id=174354 (A_core) — one-point increment in MDS was associated with 5 % (4-7 %) lower risk of all-cause death doi=10.1017/s0007114518002179

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence.

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.